Q3 2024 Revenue Estimate for Akero Therapeutics, Inc. (NASDAQ:AKRO) issued by HC Wainwright

Akero Therapeutics, Inc. (NASDAQ:AKRO – Free Report) – Investment analysts at HC Wainwright upped their Q3 2024 earnings estimates for Akero Therapeutics in a report issued on Monday, August 12th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings of ($0.85) per share for the quarter, up from their prior forecast of ($0.87). HC Wainwright presently has a “Buy” rating and a $50.00 target price on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.82) per share. HC Wainwright also issued estimates for Akero Therapeutics Q4 2024 Earnings at ($0.88) EPS, FY2024 Earnings at ($3.44) EPS, Q1 2025 Earnings at ($0.91) EPS, Q2 Earnings at ($0.91) EPS 2025 at ($2025 Revenue at ($6.0 $3.92) ) EPS Q4 2025 Earnings at ($0.96) EPS FY2025 Earnings at ($3.77) EPS FY2026 Earnings at (3 $.57) EPS, FY2027 earnings at ($1.43) EPS and FY2028 earnings at $1.4.

A number of other equities research analysts have recently issued reports on the stock. Evercore ISI cut their price target on shares of Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a report on Wednesday, May 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. Canaccord Genuity Group decreased their target price on shares of Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating for the company in a report on Monday, May 13th. Wolfe Research assumed coverage on shares of Akero Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating on the stock. Finally, Bank of America started coverage on Akero Therapeutics in a research note on Monday, April 22nd. They set a “neutral” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Moderate Buy” and an average target price of $41.13, based on data from MarketBeat.

See the latest stock report on AKRO

Akero Therapeutics trading up 2.4%

NASDAQ AKRO opened at $24.77 on Wednesday. The company has a market cap of $1.71 billion, a P/E ratio of -7.74 and a beta of -0.28. Akero Therapeutics has a 12-month low of $11.25 and a 12-month high of $53.77. The company has a debt-to-equity ratio of 0.04, a current ratio of 30.12, and a quick ratio of 30.12. The company has a 50-day moving average of $24.43 and a 200-day moving average of $23.25.

Akero Therapeutics (NASDAQ:AKRO – Get Free Report ) last posted its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.09.

Institutional inputs and outputs

Several institutional investors and hedge funds have recently bought and sold shares of AKRO. Quarry LP increased its position in Akero Therapeutics by 40.0% in the 4th quarter. Quarry LP now owns 1,750 shares of the company’s stock valued at $41,000 after acquiring an additional 500 shares during the period. Strs Ohio boosted its stake in Akero Therapeutics by 100.0% during the fourth quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $46,000 after purchasing an additional 1,000 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock worth $156,000 after acquiring an additional 1,030 shares during the period. Russell Investments Group Ltd. boosted its holdings in Akero Therapeutics by 2,366.0% in the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock valued at $31,000 after acquiring an additional 1,183 shares during the last quarter. Finally, Headlands Technologies LLC bought a new position in shares of Akero Therapeutics in the 4th quarter valued at approximately $28,000.

Insider Trading at Akero Therapeutics

In related news, COO Jonathan Young sold 5,000 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $19.29, for a total transaction of $96,450.00. Following the transaction, the chief operating officer now directly owns 253,306 shares in the company, valued at $4,886,272.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC’s website. In other news, insider Catriona Yale sold 2,825 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $22.64, for a total transaction of $63,958.00. Following the completion of the transaction, the insider now owns 74,867 shares of the company’s stock, valued at $1,694,988.88. The sale was disclosed in a filing with the SEC, which is accessible via this hyperlink. Also, COO Jonathan Young sold 5,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $19.29, for a total transaction of $96,450.00. Following the transaction, the chief operating officer now owns 253,306 shares of the company’s stock, valued at approximately $4,886,272.74. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 205,529 shares of company stock worth $5,452,376. Insiders own 7.94% of the company’s shares.

About Akero Therapeutics

(Get a free report)

Akero Therapeutics, Inc, together with its subsidiary, is engaged in the development of treatments for patients with serious metabolic diseases in the United States. The company’s lead product candidate is efruxifermin (EFX), which is in phase 3 clinical trials that protects against cellular stress and regulates lipid, carbohydrate and protein metabolism throughout the body for the treatment of steatohepatitis associated with biopsy-proven metabolic dysfunction (MASH) patients.

Featured stories

Get news and reviews for Akero Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Akero Therapeutics and related companies with MarketBeat.com ‘s FREE daily newsletter.